Verona Pharma Announces US FDA Approval of Ohtuvayre™ …
Jun 26, 2024 · Verona has evaluated nebulized Ohtuvayre in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ohtuvayre met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function.
Verona Pharma Press Releases & Updates
Jan 7, 2025 · Follow Verona Pharma’s latest updates through our press releases. Stay informed on financial results, strategic financing, clinical developments, and upcoming presentations as we advance respiratory treatments.
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE …
Sep 30, 2024 · Verona has evaluated nebulized Ohtuvayre in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ohtuvayre met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function.
Verona Pharma Announces the US FDA has Accepted the New …
Sep 11, 2023 · Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than 10 years. We believe its bronchodilator and non-steroidal...
Verona cuts $400m loan deal as it preps COPD drug for market
3 days ago · Verona Pharma has agreed a new $400 million debt facility with Oxford Finance and Hercules Capital designed to help the company navigate the possible approval and launch of ensifentrine, its...
Verona’s first-in-class COPD drug ‘could transform market’
5 days ago · Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster.
Verona prepares for US launch of ensifentrine for COPD
May 29, 2024 · Verona intends to submit an investigational new drug application to the FDA to initiate a Phase II clinical trial assessing the efficacy and safety of a fixed-dose combination formulation of the candidate drug and glycopyrrolate (a LAMA) as maintenance treatment for COPD patients via nebulisation.
US FDA Approves Verona Pharma's Inhaled COPD Therapy - U.S. News …
Jun 26, 2024 · (Reuters) -The U.S. Food and Drug Administration has granted approval to a treatment from Verona Pharma for a chronic lung disease that commonly affects smokers, the U.K.-based company said on...
Verona says COPD drug is off to a flying start | pharmaphorum
Jan 7, 2025 · Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the...
Verona Pharma Stock Catapulted 19% Over Four Days — Here's …
Jan 16, 2025 · Verona Pharma (VRNA) stock hit a record high Thursday — running up 19% over the past four days — on continued enthusiasm for its COPD treatment, Ohtuvayre. Ohtuvayre won Food and Drug...